Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 688 results
Found 688 results.

2014

F Romo T, Smeaton LM, Campbell TB, et al. "Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175)." HIV Clin Trials. 2014;15(6):246-60.
Mwafongo A, Nkanaunena K, Zheng Y, et al. "Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine." AIDS. 2014;28(8):1135-42.
Shikuma CM, Gangcuangco LMar A, Killebrew DA, et al. "The role of HIV and monocytes/macrophages in adipose tissue biology." J. Acquir. Immune Defic. Syndr.. 2014;65(2):151-9.
Shiboski CH, Chen H, Ghannoum MA, et al. "Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2014;18(6):682-8.
Sulkowski MS, Kang M, Matining R, et al. "Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study." J. Infect. Dis.. 2014;209(5):658-67.
Haas DW, Kwara A, Richardson DM, et al. "Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes." J. Antimicrob. Chemother.. 2014;69(8):2175-82.
Sandler NG, Zhang X, Bosch RJ, et al. "Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection." J. Infect. Dis.. 2014;210(10):1549-54.
Venuto CS, Mollan K, Ma Q, et al. "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202." J. Antimicrob. Chemother.. 2014;69(12):3300-10.
Tenorio AR, Zheng Y, Bosch RJ, et al. "Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment." J. Infect. Dis.. 2014;210(8):1248-59.
Luetkemeyer AF, Kendall MA, Nyirenda M, et al. "Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs." J. Acquir. Immune Defic. Syndr.. 2014;65(4):423-8.
Kang M, Hollabaugh K, Pham V, et al. "Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort." J. Acquir. Immune Defic. Syndr.. 2014;66(2):172-80.

2013

Amorosa VK, Luetkemeyer A, Kang M, et al. "Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial." HIV Clin Trials. 2013;14(6):274-83.
Atkinson BE, Krishnan S, Cox G, Hulgan T, Collier AC. "Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES." PLoS ONE. 2013;8(6):e65306.
McLaren PJ, Coulonges C, Ripke S, et al. "Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls." PLoS Pathog.. 2013;9(7):e1003515.
Taiwo B, Matining RM, Zheng L, et al. "Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy." J. Antimicrob. Chemother.. 2013;68(8):1857-61.
Brown TT, Chen Y, Currier JS, et al. "Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals." J. Acquir. Immune Defic. Syndr.. 2013;63(3):323-30.
Huang JS, Hughes MD, Riddler SA, Haubrich RH. "Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142." HIV Clin Trials. 2013;14(5):224-34.
Taiwo B, Hunt PW, Gandhi RT, et al. "CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2013;63(1):101-4.
McComsey GA, Daar ES, O'Riordan MA, et al. "Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202." J. Infect. Dis.. 2013;207(4):604-11.
Fiscus SA, Cu-Uvin S, Eshete ATilahun, et al. "Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy." Clin. Infect. Dis.. 2013;57(2):290-7.
Thio CL, Smeaton L, Saulynas M, et al. "Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort." AIDS. 2013;27(2):191-201.
Vardhanabhuti S, Acosta EP, Ribaudo HJ, et al. "Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission." J. Infect. Dis.. 2013;208(4):662-71.
Wohl DA, Kendall MA, Feinberg J, et al. "The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit." PLoS ONE. 2013;8(11):e78676.
Godfrey C, Villa C, Dawson L, Swindells S, Schouten JT. "Controlling healthcare-associated infections in the international research setting." J. Acquir. Immune Defic. Syndr.. 2013;62(4):e115-8.
Zheng L, Rosenkranz SL, Taiwo B, Para MF, Eron JJ, Hughes MD. "The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients." AIDS Res. Hum. Retroviruses. 2013;29(4):652-7.
Zhang X, Tierney C, Albrecht M, et al. "Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146." Ther Drug Monit. 2013;35(2):209-16.
Funderburg NT, Andrade A, Chan ES, et al. "Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine." PLoS ONE. 2013;8(12):e83514.
Kelesidis T, Yang OO, Kendall MA, Hodis HN, Currier JS. "Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults." Lipids Health Dis. 2013;12:23.
Grant PM, Tierney C, Budhathoki C, et al. "Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202." HIV Clin Trials. 2013;14(6):284-91.
Overton ET, Kitch D, Benson CA, et al. "Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death." Clin. Infect. Dis.. 2013;56(10):1471-9.

Pages